Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 9, 2022 - Issue
Submit an article Journal homepage
96
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Ahmed O Kaseb1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
,
Yinghui Guan2 Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USAView further author information
,
Betul Gok Yavuz1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Alexander R Abbas2 Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USAView further author information
,
Shan Lu2 Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USAView further author information
,
Elshad Hasanov3 Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-7195-0842View further author information
ORCID Icon,
Han Chong Toh4 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, SingaporeView further author information
,
Wendy Verret5 Product Development, Genentech Inc, South San Francisco, CA, USAView further author information
&
Yulei Wang2 Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9057-9786View further author information
ORCID Icon show all
Pages 1065-1079 | Received 22 Apr 2022, Accepted 16 Jul 2022, Published online: 11 Oct 2022

References

  • Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Hepatology. 2001;33:473–475. doi:10.1053/jhep.2001.22481
  • Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology. 1987;7:660–664. doi:10.1002/hep.1840070408
  • Vauthey JN, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289–299. doi:10.1111/j.1477-2574.2010.00181.x
  • Durand F, Valla D. Assessment of the prognosis of cirrhosis: child–Pugh versus MELD. J Hepatol. 2005;42(suppl 1):S100–S107. doi:10.1016/j.jhep.2004.11.015
  • Kaseb AO, Xiao L, Hassan MM, et al. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014;106:dju088. doi:10.1093/jnci/dju088
  • Daughaday WH. Editorial: the possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology. 1990;127:1–4. doi:10.1210/endo-127-1-1
  • Abdel-Wahab R, Shehata S, Hassan MM, et al. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015;2:131–142. doi:10.2147/JHC.S81309
  • Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011;29:3892–3899. doi:10.1200/JCO.2011.36.0636
  • Lacin S, Yalcin S, Karakas Y, et al. Prognostic significance of serum insulin-like growth factor-1 in hepatocellular cancer patients: a validation study. J Hepatocell Carcinoma. 2020;7:143–153. doi:10.2147/JHC.S258930
  • Abdel-Wahab R, Shehata S, Hassan MM, et al. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget. 2015;6:21193–21207. doi:10.18632/oncotarget.4176
  • Huber Y, Bierling F, Labenz C, et al. Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort. BMC Cancer. 2018;18:774. doi:10.1186/s12885-018-4677-y
  • Lee DH, Lee JH, Jung YJ, et al. Validation of a modified Child-Turcotte-Pugh classification system utilizing insulin-like growth factor-1 for patients with hepatocellular carcinoma in an HBV endemic area. PLoS One. 2017;12:e0170394. doi:10.1371/journal.pone.0170394
  • Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. doi:10.1056/NEJMoa1915745
  • Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated overall survival data from a global, randomised, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma. Presented at the Digital Liver Cancer Summit, European Association for the Study of the Liver; 2021.
  • Su WW, Lee KT, Yeh YT, et al. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 2010;24:195–200. doi:10.1002/jcla.20320
  • Kaseb AO, Abbruzzese JL, Vauthey JN, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373–381. doi:10.1159/000329040
  • Cho EJ, Lee J-H, Yoo J-J, et al. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study. Clin Cancer Res. 2013;19:4218–4227. doi:10.1158/1078-0432.CCR-12-3443

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.